



Member Newsletter

2021 No. 010

Dear Member/Student,

Welcome to the latest World Trichology Society newsletter.

For WTS News, please go to the 'Announcement' page of the website:

<https://worldtrichologysociety.org/society/forums/forum/announcements/>

Current Trichological and Health News

1. Oral Minoxidil Well-Tolerated In Patients With Alopecia, Physician Says

In an interview with [Dermatology World](#), Antonella Tosti, MD, discussed her recent [findings](#) published in JAAD showing that oral minoxidil is well tolerated in patients with hair loss. She said, “The most common side effect is hypertrichosis, but only a few patients decided to interrupt the treatment because of that (0.5% of cases).” Tosti added, “I am increasingly using oral minoxidil as I feel more confident about tolerability. It improves the hair density overall, and is useful in all types of alopecia in association with other treatments.”

2. Frontal fibrosing alopecia and facial care products

A study published in *The Journal of Dermatology* sought to investigate whether there may be an association between the use of facial care products and frontal fibrosing alopecia (FFA) in Asian females. The authors sent a survey to 50 FFA patients, 100 pattern hair loss patients, and 100 controls, inquiring about their use of facial care products and hair care practices. The use of facial moisturizer was significantly higher in the FFA group than in the control group (78% vs. 40%), and the use of sunscreen was significantly higher in the pattern hair loss group than in the control group (72% vs. 35%). Subjects in the FFA and pattern hair loss groups reported more frequent use of both sunscreen and moisturizer compared with normal controls. The authors suggest, however, that the use of facial care products, particularly moisturizer and sunscreen, may not be truly associated with FFA. The increased rate of facial care product use in patients diagnosed with hair disorders may not be linked to the disease mechanism of FFA, but rather to appearance-related concerns of patients.

3. Lawsuit filed against FDA alleged inaction on hair loss drug potential side effects

The consumer advocacy group Public Citizen filed a lawsuit on behalf of the Post-Finasteride Syndrome Foundation against the U.S. Food and Drug Administration (FDA), alleging that the agency failed to act on a petition submitted by the foundation four years ago, according to a report from [Medscape](#). The petition requested that the FDA remove finasteride, 1 mg, from the market due to evidence of serious risk of patient injury, including depression and suicidal ideation. As an alternative ask, the foundation requested that the FDA ensure the revision of safety information, including a boxed warning to disclose the potential for side effects. The foundation also noted that Canadian and European regulators do require a warning about suicide, and advise that treatment be discontinued if a patient becomes depressed.

4. Research In Alopecia Pathogenesis, Treatments

[Dermatology World](#) highlights “advances in the pathogenesis and treatments for androgenetic alopecia, alopecia areata, and central centrifugal cicatricial alopecia,” conditions that dermatologists know carry more than a “cosmetic concern.” Researchers are investigating stem cells, JAK inhibitors, etrasimod, anti-fibrotic therapies, and topical metformin among other potential treatments in various hair loss conditions. Regarding stem cells, the article says, “While recent years have brought impressive scientific breakthroughs in stem cell research for hair loss, there are still many unanswered questions about safety and cost of the procedure as well as the aesthetics of the regrown hair.”

5. Flu, COVID Vaccines Can Be Co-administered

[Medscape](#) reported the CDC’s “latest round of recommendations regarding seasonal influenza vaccines...contained one notable update: flu vaccines and COVID-19 vaccines can now be given simultaneously.” The change “stands in marked contrast to previous recommendations, in which the CDC said that other vaccinations should not be administered within a 2-week window before or after receiving the COVID-19 vaccine.” The [update](#) was published in the CDC’s Morbidity and Mortality Weekly Report.

6. A review of spironolactone for androgenetic alopecia

In a study published in *JAAD*, the authors reviewed 12 studies in which participants used spironolactone for androgenetic alopecia. Spironolactone was the sole therapy for 23% of the participants while the rest used the drug in combination with topical minoxidil, oral minoxidil, low-level laser therapy, or iron supplementation. Doses of spironolactone ranged between 25 and 200 mg for a duration of six months to four years. With the monotherapy, about half of patients achieved improvement in follicular density and hair loss. Spironolactone was ineffective at doses less than 100 mg; rather, improvement was reported after at least 12 months of 100 to 200 mg daily.

Journal Articles

For journal publications, click on the URL under the title of the topic you wish to see and it will open to a **free** abstract of the article. For obtaining the full article, just follow the relevant prompts on the site (*a payment may be required for the full article*).



1. **Alopecia in hereditary mucoepithelial dysplasia**

Kerrie G. Satcher MD, Jennifer J. Schoch MD, Addie Walker MD

<https://onlinelibrary.wiley.com/doi/abs/10.1111/cup.14124?>



1. **Contact dermatitis to hair cosmetics: Current diagnostic recommendations**

Zita-Rose Manjaly Thomas, Dagmar Jamiolkowski, Sibylla Chantraine, Esther Steveling-Klein, Kathrin Scherer Hofmeier, Karin Hartmann

<https://onlinelibrary.wiley.com/doi/abs/10.1111/ddg.14544?>



1. **Skin microbiome alterations in seborrheic dermatitis and dandruff: A systematic review**

Rong Tao, Ruoyu Li, Ruojun Wang

<https://wly-reg.onecount.net/onecount/redirects/index.php?>

1. **A rare case of alopecia areata incognita**

Vladimir Pinegin MD, PhD, Natalia Teplyuk MD, PhD, Anfisa Lepekhova MD, PhD

<https://onlinelibrary.wiley.com/doi/abs/10.1111/ijd.15780?>

1. **Oxidative stress in the skin: Impact and related protection**

Juanjuan Chen, Yang Liu, Zhao Zhao, Jie Qiu

<https://onlinelibrary.wiley.com/doi/full/10.1111/ics.12728?>

2. **Comparison of whole-head and split-head design for the clinical evaluation of anti-dandruff shampoo efficacy**

Yuanyuan Diao, Jane R. Matheson, Yingying Pi, Fiona L. Baines, Shuliang Zhang, Yuanpei Li

<https://onlinelibrary.wiley.com/doi/full/10.1111/ics.12718?>

1. **Virtual group visits to reduce psychosocial distress and racial disparities in pediatric vitiligo and alopecia areata patients**

Natalia N. Khosla M.Sc, Karina Grullon BS, Adena E. Rosenblatt M.D., Ph.D

<https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.14782?>



1. **Optimal choice of punch size for follicular unit excision: A comparative study of 153 Asian patients**

Koji Kanayama MD, Harunosuke Kato MD, et al.

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.14408?>

2. **Telogen effluvium in daily practice: Patient characteristics, laboratory parameters, and treatment modalities of 3028 patients with telogen effluvium**

Ahu Yorulmaz MD, Yildiz Hayran MD, Ahmet Kagan Ozdemir MD, et al.

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.14413?>

3. **Alopecia areata: A psychodermatological perspective**

Julio Torales MSc, João Mauricio Castaldelli-Maia PhD, et al.

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.14416?>



1. **Therapeutic approach with squaric acid dibutylester for steroid resistant-alopecia areata incognita: A pilot study of a single center**

Michela Starace, Roberta Vezzoni, Aurora Alessandrini, et al.

<https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.15096?>

2. **Is the severity of initial sensitization to diphenylcyclopropenone in alopecia areata patients predictive of the final clinical response?**

Narges Ghandi M.D., Golnoosh Seifi M.D., Maryam Nasimi M.D., Robabeh Abedini M.D., Soheila Mirabedian M.D., Ifa Etesami M.D.-MPH, Amirhooshang Ehsani M.D.

<https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.15118?>

1. **Histopathological differential diagnosis of frontal fibrosing alopecia and fibrosing alopecia in a pattern distribution**
M.S. Teixeira, M.F.R. Gavazzoni Dias, E.A.G. Vilar, L. Pantaleão, et al.
<https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.20592?>
2. **Clinical characteristics of male frontal fibrosing alopecia: A single-centre case series from London, United Kingdom**
T. Rayinda, S.M. McSweeney, N. Dand, D.A. Fenton, et al.
<https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.20742?>
3. **PPAR γ signaling protects hair follicle stem cells from chemotherapy-induced apoptosis and epithelial-mesenchymal transition**
I. Piccini, L. Brunken, J. Chéret, S. Ghatak, Y. Ramot, M. Alam, et al.
<https://wly-reg.onecount.net/onecount/redirects/index.php?>
4. **Comparing the clinical differences in white and black women with frontal fibrosing alopecia**
P. Adotama, V. Callender, A. Kolla, C. Young, P. Jones, K. Svigos, et al.
<https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.20605?>

1. **Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double-blind, placebo-controlled, phase 1B clinical trial**
L. Bokhari, L.N. Jones, R.D. Sinclair
<https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.17623?>

CONTACT DERMATITIS

CUTANEOUS ALLERGY
ENVIRONMENTAL AND OCCUPATIONAL DERMATITIS

1. **Cicatricial alopecia following allergic contact dermatitis from hair dyes: a rare clinical presentation**

Tanvi Dev MD, Ejaz Khan MBBS, Utpal Patel MD, Prof. Kaushal Verma MD, FRCP

<https://onlinelibrary.wiley.com/doi/abs/10.1111/cod.13974?>

CED

CLINICAL AND EXPERIMENTAL DERMATOLOGY
THE EDUCATIONAL JOURNAL OF THE BRITISH ASSOCIATION OF DERMATOLOGISTS



1. **Is heritability of alopecia areata sex-specific? A nationwide population-based cohort study**

C.-K. Wong, Y.-L. Chen, R. C. Hsiao, S. C.-S. Hu, C.-F. Yen

<https://onlinelibrary.wiley.com/doi/abs/10.1111/ced.14836?>

QUESTION FOR CTE® CREDIT (FOR FULL MEMBERS ONLY): PLEASE EMAIL ANSWER TO: KERRI@WORLDTRICHOLOGYSOCIETY.ORG

In Yorulmaz et al.'s research article regarding " Telogen Effluvium in daily practice", which two serum test types were performed the most?

©2021 World Trichology Society
www.WorldTrichologySociety.org
Email: info@WorldTrichologySociety.org
T: 1-718-698-4700